Berkeley Lights, Inc.: directors' dealings · United States · SEC (Form 4)

About Berkeley Lights, Inc.

Berkeley Lights, Inc. was a U.S.-based life sciences and healthcare technology company, historically listed on the NASDAQ under the ticker BLI in the United States. Incorporated in 2011 and headquartered in Emeryville, California, the company built its business around digital cell biology and research tools designed to accelerate the development and commercialization of biotherapeutics and other cell-based products. Its core strategy centered on an integrated platform combining proprietary consumables, automation systems, and workflow software to capture and analyze thousands of individual cells in parallel. From an operating perspective, Berkeley Lights positioned itself as a provider of single-cell biology and functional discovery solutions for pharmaceutical companies, biotech firms, and research laboratories. Its flagship offering was the Berkeley Lights Platform, supported by OptoSelect chips, reagent kits, advanced automation systems, and application/workflow software. The company also introduced desktop and benchtop systems such as Lightning and Culture Station, which were intended for assay development and lower-throughput workflows. This hardware-software-consumables model was designed to create recurring revenue opportunities and deepen customer relationships beyond one-off instrument sales. Geographically, Berkeley Lights expanded beyond the United States. SEC filings indicate it established operations in the United Kingdom to support European expansion and a foreign operating entity in China to broaden its reach in Asia. That footprint reflected the company’s ambition to commercialize a specialized platform globally, targeting markets where pharmaceutical R&D spending and demand for advanced cell-analysis workflows are structurally important. In competitive terms, Berkeley Lights operated in a niche but highly contested segment of the life sciences tools industry, competing with other players in single-cell analysis, microfluidics, cell sorting, and functional biology research platforms. Its differentiation rested on workflow integration, deep per-cell phenotypic and genotypic insight, and the promise of accelerating the identification of biologically relevant cells for therapeutic development. At the same time, the business was exposed to long sales cycles, uneven capital spending by customers, and fast-moving technological competition. The most important recent corporate development was strategic rather than operational: in 2023, Berkeley Lights merged with IsoPlexis, the combined company was renamed PhenomeX, and then the business was acquired by Bruker in October 2023. As a result, Berkeley Lights no longer trades as an independent public company. For investors tracking SEC Form 4 insider activity, the Berkeley Lights name now mainly refers to the company’s historical legacy and underlying technology platform rather than an active standalone NASDAQ-listed issuer.